Deloitte’s 2026 Healthcare Outlook: Key Findings on Confidence, Digital Health, AI and Partnerships

Deloitte’s 2026 Healthcare Outlook shows that while more than two-thirds of U.S. healthcare leaders expect to outperform competitors, rising policy uncertainty is pushing greater focus on digital care, AI and partnerships. The post Deloitte’s 2026 Healthcare Outlook: Key Findings on Confidence, Digital Health, AI and Partnerships appeared first on MedCity News.

Read More

AHA Invests in AI that Tackles Cardiology’s Gender Bias Problem

The American Heart Association is backing an AI startup aimed at improving detection of hard-to-diagnose conditions like cardiac amyloidosis and heart failure with preserved ejection fraction (HFpEF). The company, named Ultromics, offers a platform that analyzes routine echocardiograms to help clinicians catch disease earlier, particularly for women who are more likely to be missed. The…

Read More

FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med

Cytokinetics drug Myqorzo won FDA approval for treating obstructive hypertrophic cardiomyopathy, or oHCM. Compared to Bristol Myers Squibb’s projected blockbuster drug Camzyos, the Cytokinetics daily pill has less restrictive safety and monitoring requirements, giving it a competitive advantage, according to analysts. The post FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS…

Read More

New Trump Administration Proposals Would Further Limit Gender Affirming Care for Young People by Restricting Providers and Reducing Coverage

This brief examines two proposed federal rules that would further restrict youth access to gender affirming care. One rule would change the hospital Conditions of Participation (CoPs) which would prohibit most Medicare and Medicaid enrolled hospitals from providing certain types of gender affirming medical care for young people and the other would prohibit federal Medicaid…

Read More